Table 3.
Comparison of all-cause, infection related, CV-related, and cancer-related death.
| All N, 1486 | G1 N, 136 | G2 N, 430 | G3 N, 543 | G4 N, 245 | G5 N, 132 | |
|---|---|---|---|---|---|---|
| All-cause death* | 381, 25.6 | 40, 29.4 | 96, 22.3 | 134, 24.7 | 67, 27.3 | 44, 33.3 |
| Model 1 | 1.26 (0.87 − 1.82) | Reference | 1.18 (0.91 − 1.53) | 1.35 (0.99 − 1.84) | 1.63 (1.14 − 2.33)*** | |
| Model 2 | 1.07 (0.72 − 1.60) | Reference | 1.27 (0.96 − 1.69) | 1.63 (1.16 − 2.30)*** | 1.78 (1.19 − 2.68)*** | |
| Model 3 | 0.80 (0.50 − 1.27) | Reference | 1.03 (0.66 − 1.60) | 1.41 (0.84 − 2.35) | 1.44 (0.81 − 2.57) | |
| Infection-related death* | 87, 5.9 | 9, 6.6 | 18, 4.2 | 32, 5.9 | 14, 5.7 | 14, 10.6 |
| Model 1 | 1.49 (0.67 − 3.31) | Reference | 1.54 (0.86 − 2.74) | 1.57 (0.78 − 3.15) | 2.75 (1.37 − 5.54)*** | |
| Model 2 | 1.09 (0.47 − 2.57) | Reference | 1.65 (0.91 − 3.01) | 1.80 (0.85 − 3.84) | 3.09 (1.45 − 6.59)*** | |
| Model 3 | 0.74 (0.28 − 1.97) | Reference | 1.48 (0.61 − 3.59) | 1.83 (0.63 − 5.29) | 3.37 (1.24 − 9.15) ** | |
| CV-related death* | 149, 10.0 | 12, 8.8 | 39, 9.1 | 55, 10.1 | 27, 11.0 | 16, 12.1 |
| Model 1 | 0.96 (0.50 − 1.83) | Reference | 1.18 (0.78 − 1.77) | 1.32 (0.81 − 2.16) | 1.45 (0.81 − 2.60) | |
| Model 2 | 0.86 (0.44 − 1.67) | Reference | 1.13 (0.73 − 1.76) | 1.53 (0.90 − 2.60) | 1.27 (0.64 − 2.53) | |
| Model 3 | 1.34 (0.61 − 2.99) | Reference | 1.45 (0.66 − 3.18) | 1.93 (0.80 − 4.64) | 1.57 (0.57 − 4.31) | |
| Cancer-related death* | 65, 4.4 | 10, 7.4 | 18, 4.2 | 21, 3.9 | 10, 4.1 | 6, 4.5 |
| Model 1 | 1.67 (0.77 − 3.61) | Reference | 1.03 (0.55 − 1.94) | 1.11 (0.51 − 2.41) | 1.20 (0.47 − 3.01) | |
| Model 2 | 1.73 (0.74 − 4.02) | Reference | 1.33 (0.66 − 2.69) | 1.61 (0.68 − 3.82) | 1.57 (0.53 − 4.61) | |
| Model 3 | 0.34 (0.13 − 0.90)** | Reference | 0.44 (0.18 − 1.08) | 1.01 (0.38 − 2.65) | 0.56 (0.16 − 1.93) |
*Value, %, HR (95% CI).
**p < .05 and***p < .01.
G1-5 was classified by serum uric acid level.
G1; 6.0 mg/dL <, G2; 6.0 <, < 8 mg/dL, G3; 8.0 <, < 10.0 mg/dL, G4; 10.0 <, < 12.0 mg/dL, G5; < 12.0 mg/dL.
Model 1; adjusted for age and gender, Model 2; adjusted for Model 1 + diabetes, coronary artery disease, stroke, vascular access, ACEI/ARB, allopurinol, loop diuretics, thiazide, hemoglobin, albumin, eGFR, and CRP, Model 3; stepwise regression adjusted for Model 2 + BMI, primary kidney disease, cancer, dialysis modality, β-blockers, statin, ESA, BUN, creatinine, adjusted calcium, phosphate, total cholesterol, and HCO3−.
HR: hazard ratio; CI: confidence interval; CV: cardiovascular; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; BMI: body mass index; ESA: erythropoiesis-stimulating agent; BUN: blood urea nitrogen